Synaptic Deficits in Adnp-Mutant Mice Are Ameliorated by Histone Demethylase LSD1 Inhibition.
Chih-Hung Lin, Yong Ren, Kin Wai Tam and 2 others
PMID 40536108WHAT IT FOUND
In mice with an autism-related ADNP mutation, an LSD1 inhibitor increased reduced prefrontal synaptic signals, especially in females.
This is a mouse finding, not evidence that any therapy helps human autism.
Key findings
01The ADNP mutation diminished excitatory and inhibitory synaptic transmission in mouse prefrontal cortex neurons.
02GSK-LSD1 treatment rescued excitatory and inhibitory synaptic transmission in mutant mice, especially females.
03GSK-LSD1 changed histone marks in female mutant mice.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was done in mice, not people, so it does not show what happens in human brain or clinical function. The outcome was electrical current in brain slices, not speech, movement, daily skills, or autism symptoms. The drug was given for only 3 days, and recordings were done 1-14 days later, so long-term effects are unknown. Male mice often showed only trends, so the rescue was not equally strong in both sexes. The paper does not give a single total mouse count; group sizes varied by experiment. The mutation model is specific, and other ADNP mutations may behave differently.
Declared interests
The paper is listed as supported by NIH extramural research. No author conflict-of-interest declaration is included.
The easy way to misread this
Do not read this as evidence that LSD1 inhibitors can treat autism in humans. The result is a mouse brain-cell measurement, not a patient outcome.